Efficacy of lanreotide 120 mg primary therapy on tumour shrinkage and ophthalmologic symptoms in acromegaly after 1 month.
Hamza BenderradjiElise VernotteGustave Soto AresJean Philippe WoillezArnaud JanninRomain PerbetMélodie-Anne KarnoubBenoît SoudanRichard AssakerLuc BueeVincent PrevotClaude-Alain MauragePascal PignyMarie-Christine VantyghemEmilie MerlenChristine CortetPublished in: Clinical endocrinology (2022)
Primary treatment with lanreotide 120 mg in patients with somatotroph macroadenomas provides early significant tumour shrinkage with rapid improvement of visual symptoms at the end of the first month in 50% of patients.